CONMED Co. (NYSE:CNMD) Position Raised by Dean Investment Associates LLC

Dean Investment Associates LLC raised its position in CONMED Co. (NYSE:CNMD - Free Report) by 49.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 37,947 shares of the company's stock after buying an additional 12,551 shares during the period. Dean Investment Associates LLC owned about 0.12% of CONMED worth $2,597,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its stake in CONMED by 93.6% in the fourth quarter. GAMMA Investing LLC now owns 726 shares of the company's stock valued at $50,000 after buying an additional 351 shares during the period. Pacer Advisors Inc. grew its stake in shares of CONMED by 41.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,656 shares of the company's stock worth $113,000 after purchasing an additional 485 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of CONMED by 19.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,962 shares of the company's stock valued at $136,000 after purchasing an additional 322 shares during the last quarter. CIBC Asset Management Inc acquired a new position in shares of CONMED in the 4th quarter valued at about $210,000. Finally, Summit Investment Advisors Inc. increased its stake in shares of CONMED by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,228 shares of the company's stock valued at $221,000 after acquiring an additional 205 shares in the last quarter.

CONMED Stock Up 4.6 %

Shares of NYSE:CNMD traded up $2.23 during trading hours on Wednesday, hitting $50.25. The company's stock had a trading volume of 238,172 shares, compared to its average volume of 462,500. The firm's fifty day moving average price is $57.74 and its 200 day moving average price is $65.43. CONMED Co. has a 52 week low of $46.00 and a 52 week high of $78.58. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.30 and a quick ratio of 1.06. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of 11.85, a P/E/G ratio of 1.83 and a beta of 1.28.

CONMED (NYSE:CNMD - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.20 by $0.14. CONMED had a return on equity of 14.31% and a net margin of 10.13%. As a group, research analysts expect that CONMED Co. will post 4.35 EPS for the current year.

CONMED Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 4th. Stockholders of record on Friday, March 14th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 1.59%. The ex-dividend date of this dividend was Friday, March 14th. CONMED's payout ratio is presently 18.87%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on CNMD shares. Stifel Nicolaus raised their price target on shares of CONMED from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Wells Fargo & Company lowered their price target on CONMED from $74.00 to $70.00 and set an "equal weight" rating on the stock in a report on Thursday, February 6th. JPMorgan Chase & Co. lowered shares of CONMED from an "overweight" rating to a "neutral" rating and lowered their price objective for the stock from $85.00 to $70.00 in a report on Thursday, February 6th. Finally, Needham & Company LLC dropped their price target on shares of CONMED from $97.00 to $91.00 and set a "buy" rating for the company in a research report on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $77.20.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.